Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 5.9% Higher

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) shot up 5.9% during mid-day trading on Thursday . The stock traded as high as $2.19 and last traded at $2.16. 284,943 shares were traded during mid-day trading, a decline of 94% from the average session volume of 4,708,926 shares. The stock had previously closed at $2.04.

Lexicon Pharmaceuticals Stock Performance

The stock has a fifty day simple moving average of $2.39 and a two-hundred day simple moving average of $1.64. The company has a debt-to-equity ratio of 1.07, a quick ratio of 5.58 and a current ratio of 5.60. The stock has a market capitalization of $507.25 million, a price-to-earnings ratio of -2.58 and a beta of 1.27.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. The company had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. Analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in LXRX. TIAA Trust National Association bought a new position in shares of Lexicon Pharmaceuticals in the 3rd quarter worth $29,000. SG Americas Securities LLC acquired a new position in shares of Lexicon Pharmaceuticals during the third quarter valued at about $64,000. Swiss National Bank increased its position in shares of Lexicon Pharmaceuticals by 4.4% during the third quarter. Swiss National Bank now owns 242,300 shares of the biopharmaceutical company's stock worth $264,000 after acquiring an additional 10,300 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of Lexicon Pharmaceuticals by 160.9% in the 3rd quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company's stock worth $43,000 after acquiring an additional 24,400 shares during the last quarter. Finally, KWB Wealth bought a new position in Lexicon Pharmaceuticals in the 4th quarter valued at about $62,000. Institutional investors and hedge funds own 74.70% of the company's stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.